173 related articles for article (PubMed ID: 35680414)
1. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
[TBL] [Abstract][Full Text] [Related]
2. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.
Harlaar NJ; Koller M; de Jongh SJ; van Leeuwen BL; Hemmer PH; Kruijff S; van Ginkel RJ; Been LB; de Jong JS; Kats-Ugurlu G; Linssen MD; Jorritsma-Smit A; van Oosten M; Nagengast WB; Ntziachristos V; van Dam GM
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):283-290. PubMed ID: 28404198
[TBL] [Abstract][Full Text] [Related]
3. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial.
Steinkamp PJ; Pranger BK; Li MF; Linssen MD; Voskuil FJ; Been LB; van Leeuwen BL; Suurmeijer AJH; Nagengast WB; Kruijff S; van Ginkel RJ; van Dam GM
J Nucl Med; 2021 Mar; 62(3):342-347. PubMed ID: 32680922
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma.
Napp J; Stammes MA; Claussen J; Prevoo HAJM; Sier CFM; Hoeben FJM; Robillard MS; Vahrmeijer AL; Devling T; Chan AB; de Geus-Oei LF; Alves F
Int J Cancer; 2018 May; 142(10):2118-2129. PubMed ID: 29277891
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.
Tummers WS; Miller SE; Teraphongphom NT; Gomez A; Steinberg I; Huland DM; Hong S; Kothapalli SR; Hasan A; Ertsey R; Bonsing BA; Vahrmeijer AL; Swijnenburg RJ; Longacre TA; Fisher GA; Gambhir SS; Poultsides GA; Rosenthal EL
Ann Surg Oncol; 2018 Jul; 25(7):1880-1888. PubMed ID: 29667116
[TBL] [Abstract][Full Text] [Related]
7. Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer.
de Jongh SJ; Tjalma JJJ; Koller M; Linssen MD; Vonk J; Dobosz M; Jorritsma-Smit A; Kleibeuker JH; Hospers GAP; Havenga K; Hemmer PHJ; Karrenbeld A; van Dam GM; van Etten B; Nagengast WB
J Nucl Med; 2020 May; 61(5):655-661. PubMed ID: 31628218
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.
Olson MT; Aguilar EN; Brooks CL; Isder CC; Muilenburg KM; Talmon GA; Ly QP; Carlson MA; Hollingsworth MA; Mohs AM
Mol Pharm; 2022 Oct; 19(10):3586-3599. PubMed ID: 35640060
[TBL] [Abstract][Full Text] [Related]
9. Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study.
van Manen L; de Muynck LDAN; Baart VM; Bhairosingh S; Debie P; Vahrmeijer AL; Hernot S; Mieog JSD
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189366
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin Assessment During Pancreatic Resection.
Newton AD; Predina JD; Shin MH; Frenzel-Sulyok LG; Vollmer CM; Drebin JA; Singhal S; Lee MK
Ann Surg; 2019 Jul; 270(1):12-20. PubMed ID: 31188797
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery.
Dijkstra BM; Nonnekens J; Nagengast W; Kruijff S; Meersma GJ; den Dunnen WFA; Kruyt FAE; Groen RJM
J Neurosurg; 2023 May; 138(5):1263-1272. PubMed ID: 36308486
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
Saccomano M; Dullin C; Alves F; Napp J
Int J Cancer; 2016 Nov; 139(10):2277-89. PubMed ID: 27428782
[TBL] [Abstract][Full Text] [Related]
13. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent.
Hoogstins CES; Boogerd LSF; Sibinga Mulder BG; Mieog JSD; Swijnenburg RJ; van de Velde CJH; Farina Sarasqueta A; Bonsing BA; Framery B; Pèlegrin A; Gutowski M; Cailler F; Burggraaf J; Vahrmeijer AL
Ann Surg Oncol; 2018 Oct; 25(11):3350-3357. PubMed ID: 30051369
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW.
Huisman LA; Steinkamp PJ; Hillebrands JL; Zeebregts CJ; Linssen MD; Jorritsma-Smit A; Slart RHJA; van Dam GM; Boersma HH
Sci Rep; 2021 Feb; 11(1):2899. PubMed ID: 33536498
[TBL] [Abstract][Full Text] [Related]
15. A novel plectin/integrin-targeted bispecific molecular probe for magnetic resonance/near-infrared imaging of pancreatic cancer.
Wang Q; Yan H; Jin Y; Wang Z; Huang W; Qiu J; Kang F; Wang K; Zhao X; Tian J
Biomaterials; 2018 Nov; 183():173-184. PubMed ID: 30172243
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE; Koch M; de Jong JS; Adams ALL; Glatz J; Kranendonk MEG; Terwisscha van Scheltinga AGT; Jansen L; de Vries J; Lub-de Hooge MN; Schröder CP; Jorritsma-Smit A; Linssen MD; de Boer E; van der Vegt B; Nagengast WB; Elias SG; Oliveira S; Witkamp AJ; Mali WPTM; Van der Wall E; van Diest PJ; de Vries EGE; Ntziachristos V; van Dam GM
Clin Cancer Res; 2017 Jun; 23(11):2730-2741. PubMed ID: 28119364
[No Abstract] [Full Text] [Related]
17. Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial.
Vergeer RA; Postma MR; Schmidt I; Korsten-Meijer AG; Feijen RA; Kruijff S; Nagengast WB; van Dijk JMC; den Dunnen WFA; van Beek AP; Kuijlen JMA; van den Berg G
BMJ Open; 2021 Oct; 11(10):e049109. PubMed ID: 34620658
[TBL] [Abstract][Full Text] [Related]
18. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer.
Tummers WS; Miller SE; Teraphongphom NT; van den Berg NS; Hasan A; Longacre TA; Fisher GA; Bonsing BA; Vahrmeijer AL; Gambhir SS; Swijnenburg RJ; Rosenthal EL; Poultsides GA
HPB (Oxford); 2019 Jul; 21(7):883-890. PubMed ID: 30723062
[TBL] [Abstract][Full Text] [Related]
19. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
